Meet the ‘Corporate Bro’ Making Millions Satirizing Tech Sales
Laugh and learn from Corporate Bro! See how Ross Pomerantz flipped SaaS sales absurdities into a multi-million-dollar brand with authentic, viral tech humor.
Technology
All categories →More from Technology
Page 11 of 37
Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion
Novartis acquires Excellergy for $2B, gaining a precision platform for severe allergy treatment. Their EX-001 candidate targets immune root causes.
The Panic Over ‘Tech Neck’—and Race for a Cure
Tech neck from screens sparks a $1.5B beauty market. Explore specialized creams, serums, and devices addressing digital wrinkles, with expert insights and skepticism.
Orbital Data-Center Startup Aetherflux Eyes $2 Billion Valuation in New Funding Round
Baiju Bhatt's Aetherflux, valued at $2B, plans solar-powered orbital data centers for AI. Addressing terrestrial computing's energy & cooling limits.
Anthropic Wins Injunction in Court Battle With Trump Administration
AI safety firm Anthropic wins injunction vs. Trump Admin over military AI push. Judge cites "coercive retaliation," setting a precedent for ethical tech.
What I Hate Most About the Technology in Hotel Rooms
Why are hotel rooms still failing on tech in 2026? Uncover the truth behind poor Wi-Fi, hidden outlets, and clunky smart TVs. Understand the industry's challenge.
Meta and YouTube Found Negligent in Social-Media Addiction Trial
Meta & YouTube negligent in addiction trial for harmful design. Learn how this landmark verdict reshapes tech's future, user safety, & company accountability.
Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets
Gilead acquires Ouro Medicines for $2.18B, leveraging its Galapagos NV partnership to boost its early-stage pipeline. Uncover this strategic R&D move.
Roche Halts Development of Drug Candidate `emugrobart` for Muscle Diseases, Chugai Confirms
Roche discontinues emugrobart, its muscle disease drug candidate, after two pivotal studies failed efficacy. Explore the impact on pharma R&D.
Going Electric? The Future's Power Surge Meets Tech's Next Wave
Are we ready for an electrified future? Unpack electric grid strain, Apple's $599 MacBook Neo, and a teen AI startup's $100M success. Discover if innovation can meet energy demands.
Our Tech Columnists’ Annual Predictions: Folding iPhones, Mind-Reading Tech, EV Supercars
Explore 2024 tech predictions: folding iPhone, mind-reading tech, EV supercars. Plus, current AI chip shifts, humanoid robots & China's AI fears.
AI Chatbots Linked to Psychosis, Say Doctors
AI chatbots are increasingly complicit in user psychosis, creating shared delusions. Explore urgent warnings from doctors impacting the generative AI industry.
Michael Burry Bets He Isn’t Too Early to Go Against the AI Juggernaut
Michael Burry, the "Big Short" investor, is shorting Nvidia & Palantir. Is he seeing an AI bubble burst, or is he too early? Unpack his Q2 moves.
Surrogacy Is a Multibillion-Dollar Business—but Surrogates Can Be Left With Big Debts
The surrogacy dream can be a financial nightmare for carriers. Uncover how the $30B market's lack of oversight leaves surrogates in debt with hidden costs.
Classroom Phone Bans Work. So Why Don’t All Schools Do It?
Explore how school phone bans boost academics (up to 6.5% test scores), improve mental health, & reduce discipline. Learn the benefits & challenges.
Tech That Will Change Your Life in 2026
Experience 2026: foldable iPhones, smart home robots, EV supercars & mind-reading tech. Uncover AI's impact on daily life, healthcare & cybersecurity.
How AI Is Making Life Easier for Cybercriminals
AI fuels a cybercrime revolution: phishing, BEC, & deepfake scams are now flawlessly convincing. Discover how AI lowers attack barriers & how to defend your organization.
Startup Lifordi Seeks to Deliver Potent Medication for Autoimmune Diseases
Lifordi Immunotherapeutics pioneers targeted antibody-drug conjugates for autoimmune diseases, aiming to deliver precise, effective care with fewer side effects.